Mucosal immunization with DNA vaccines

Area of Science:

• Immunology
• Vaccinology
• Public Health

Background:

• Mucosal surfaces (gastrointestinal, genitourinary, respiratory) have a large surface area, making them primary sites for disease transmission.
• Pathogen entry at mucosal sites requires mucosal immunity for prevention, which systemic immunity cannot provide.
• Traditional intramuscular (IM) or subcutaneous (SC) vaccines primarily induce systemic immunity, neglecting mucosal protection.

Purpose of the Study:

• To highlight the advantages of mucosal vaccines over systemic vaccines.
• To emphasize the role of mucosal immunity in preventing infections at mucosal surfaces.
• To advocate for the development and use of mucosal vaccine delivery methods.

Main Methods:

• Review of existing literature on vaccine delivery routes and immune responses.
• Comparison of immune responses elicited by mucosal versus systemic vaccine administration.
• Analysis of safety and logistical benefits of mucosal immunization.

Main Results:

• Mucosal vaccine delivery triggers both local and distant mucosal immunity, as well as systemic immunity.
• Intramuscular (IM) or subcutaneous (SC) injections primarily induce systemic immunity, with limited mucosal protection.
• Mucosal vaccines offer advantages like broader age applicability, ease of administration, and no risk of needle-related injuries.

Conclusions:

• Mucosal immunization is a superior strategy for preventing diseases transmitted via mucosal surfaces.
• Developing and implementing mucosal vaccines can enhance protection against a wide range of pathogens.
• The non-invasive nature and broader benefits make mucosal vaccines a promising approach for future immunization programs.